One of these tumours was treatment-naïve (RMH004), one had been treated for 16 weeks before surgery with the anti-angiogenic drug sunitinib (RMH002) and two had been treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus for 6 weeks before the tumours were removed by surgery (EV003 and EV004) (for clinical and pathological characteristics, see Table 1). This evidence concerns the gene MTOR and neoplasm.